Literature DB >> 11923142

Initial antiretroviral regimens.

Charles Carpenter.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 11923142      PMCID： PMC1122691          DOI： 10.1136/bmj.324.7340.747

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Authors:  G R Kaufmann; M Bloch; J J Zaunders; D Smith; D A Cooper
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

2.  British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.

Authors: 
Journal:  HIV Med       Date:  2001-10       Impact factor: 3.180

3.  Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.

Authors:  S G Deeks; N S Hellmann; R M Grant; N T Parkin; C J Petropoulos; M Becker; W Symonds; M Chesney; P A Volberding
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

4.  Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; T el-Shourbagy; P Baroldi; K Erdman; F Brown; E Sun; J M Leonard
Journal:  Clin Pharmacol Ther       Date:  1998-04       Impact factor: 6.875

Review 5.  Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; D A Cooper; M A Fischl; J M Gatell; B G Gazzard; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; M Schechter; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  2000-01-19       Impact factor: 56.272

6.  Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.

Authors:  Rachel Jordan; Lisa Gold; Carole Cummins; Chris Hyde
Journal:  BMJ       Date:  2002-03-30

7.  Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy.

Authors:  G Pantaleo; O J Cohen; T Schacker; M Vaccarezza; C Graziosi; G P Rizzardi; J Kahn; C H Fox; S M Schnittman; D H Schwartz; L Corey; A S Fauci
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

8.  ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.

Authors:  H L Sham; D J Kempf; A Molla; K C Marsh; G N Kumar; C M Chen; W Kati; K Stewart; R Lal; A Hsu; D Betebenner; M Korneyeva; S Vasavanonda; E McDonald; A Saldivar; N Wideburg; X Chen; P Niu; C Park; V Jayanti; B Grabowski; G R Granneman; E Sun; A J Japour; J M Leonard; J J Plattner; D W Norbeck
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.